1. Introduction {#sec1-jcm-06-00049}
===============

Behcet's disease (BD) is a chronic disorder, and its manifestations are thought to originate from autoinflammatory-based vasculitis. Inflammation can also derive from arthropathies and vasculopathies in the central nervous system \[[@B1-jcm-06-00049],[@B2-jcm-06-00049]\]. Diagnosis of this syndrome is based on clinical aspects and internationally accepted criteria. This syndrome affects young men and women in the Mediterranean, the Middle East, and the Far East regions, which reveals the possibility of a relationship between the ancient Silk Road regions and the prevalence of the BD. This syndrome affects male and female equally but severe cases occur more in males \[[@B3-jcm-06-00049]\]. The main pathological view shows systemic perivasculitis with neutrophilic infiltration and endothelial cell swelling. A large number of infiltrative CD4+ T cells as well as neutrophils are also seen in lesions \[[@B4-jcm-06-00049]\]. Increases or changes in the levels of certain cytokines in BD has been demonstrated in many studies \[[@B5-jcm-06-00049],[@B6-jcm-06-00049],[@B7-jcm-06-00049]\]. BD is known as autoimmune disease due to increased levels of immunoglobulins, immune complexes, and acute phase proteins \[[@B8-jcm-06-00049]\]. Abnormality in endothelial cells and neutrophils is assumed as the starting points for many clinical manifestations of BD. Due to the activation of the immune system, cytokines, and inflammatory mediators can modulate the disease process \[[@B9-jcm-06-00049]\]. BD uveitis is a chronic uveitis associated with necrotizing vasculitis in the retina, and it can give rise to bilateral blindness that is needed for heavy immunosuppression. Recent studies have shown that immune factors in BD uveitis are distinguishable from the other endogenous uveitis \[[@B5-jcm-06-00049],[@B10-jcm-06-00049]\]. The association between cytokines and uveitis has been already mentioned in a limited number of studies, but their methods of implementation or analysis of cytokines have been partly imperfect \[[@B11-jcm-06-00049],[@B12-jcm-06-00049],[@B13-jcm-06-00049]\]. Thus, it is desirable to perform an appropriate implementation method as well as evaluating more number of cytokines particularly in the case of uveitis as one of the most terrifying status in BD.

2. Materials and Method {#sec2-jcm-06-00049}
=======================

This study was designed to evaluate biomarkers and cytokines entitled VEGF, IFNγ, TNFα, IL-17, IL-15, IL-12, IL-10, IL-8, IL-6, IL-4, and IL-2 in venous blood samples of patients who divided in three groups and handled by subsequent statistical approach. This survey was done on patients referred to a rheumatology clinic in a university hospital in Zanjan, Iran. The research followed the tenets of the Declaration of Helsinki; detailed design of the study was explained to the patients and their families and/or legal guardians. Written informed consent was obtained from all subjects and their legal executors. Ethical permission was obtained, all information remained confidential and mural aspects of study were accepted in details of the plan adopted in the Medical Ethics Committee of Zanjan University of Medical Sciences. Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission, and redundancy) have been completely observed by the authors.

Patients with confirmed diseases based on New International Criteria for BD (ICBD) were divided in three groups according to the ophthalmologic exam results: BD with uveitis, BD without uveitis, and recovered uveitis BD. Patients with a post-recovery history of BD uveitis for at least 3--6 months were placed in the group entitled "recovered uveitis BD". The patients with infectious uveitis, other collagen vascular diseases and biologic drug users were excluded as well. Age, sex, and Pathergy test results were obtained for each patient as well. A quantity of 10 ml of venous blood was taken and was frozen at −70 °C after centrifugation at 3000 rpm to separate the serum. Subsequently, collected samples were conducted for evaluation of VEGF, IFNγ, TNFα, IL-17, IL-15, IL-12, IL-10, IL-8, IL-6, IL-4, and IL-2 levels using Enzyme Linked Immunosorbent assay (ELISA) method via kits (Bioassay Technology Co., Shanghai, China). The test sensitivity of each corresponding kits were 2.33, 2.52, 1.02, 2.43, 1.13, 2.52, 1.98, 0.98, 1.52, 0.49, and 10.25 ng/L respectively. Intra assay precision (CV \< 10%) and Inter assay precision (CV \< 12%) were done using another ELISA processor. Analysis of variance (ANOVA) and Kruskal--Wallis tests were used for quantitative variables with normal distribution and for non-normally distributed variables respectively. Additionally, Bonferroni correction test and Mann--Whitney U post-hoc test were done separately to weigh against the two groups.

3. Results {#sec3-jcm-06-00049}
==========

Seventy-five patients participated in three groups based on clinical examination and already-mentioned diagnostic criteria ([Table 1](#jcm-06-00049-t001){ref-type="table"}). The following results were obtained after measurement of serum cytokines and analyzed them in all three groups ([Table 2](#jcm-06-00049-t002){ref-type="table"}). Results of data analysis of IL-2 serum levels in the three groups were as follows: BD without uveitis (mean = 537, SD = 568), BD with uveitis (mean = 1184, SD = 1658), and recovered uveitis BD (mean = 506, SD = 491), respectively. Additionally, due to the non-normal distribution of data, the median was calculated to balance three groups: BD without uveitis (median = 376), BD with uveitis (median = 542), and recovered uveitis BD (median = 365). Significant differences in IL-2 serum levels were observed among groups after a median comparison (*p*~value~ = 0.02).

The Mann--Whitney U test showed significant differences between IL-2 serum levels of groups entitled "BD with uveitis" and "recovered uveitis BD" (*p*~value~ = 0.002). A significant difference in IL-2 serum levels between the "BD with uveitis" group and the "BD without uveitis" group was also observed (*p*~value~ = 0.004), but no significant difference was observed between "BD without uveitis" and "recovered uveitis BD" groups (*p*~value~ = 0.47). No significant differences were observed among other items.

4. Discussion {#sec4-jcm-06-00049}
=============

Results showed that only IL-2 increased in cases of active uveitis, and, after treatment (without any using of biologic agents), it decreased in cases of recovered uveitis BD. Other cytokines did not show any significant changes in the three groups, so its pathogenic role in BD with uveitis was not proven in our study. The increase of IL-2 in BD patients with active uveitis and the decrease in BD cases without uveitis and recovered BD uveitis could be evidence for the role of CD4**^+^**T helper cells in patients with uveitis \[[@B12-jcm-06-00049],[@B13-jcm-06-00049]\]. Because only 40% of BD patients with active uveitis were enrolled in the study, there was no statistical difference between IL-2 levels in the BD uveitis group compared to uveitis cases in the study of Nalbant et al. \[[@B14-jcm-06-00049]\]. Our findings showed results that were identical to Sugiet et al.'s study with similar findings with respect to IL-2 levels in cases of BD uveitis \[[@B15-jcm-06-00049]\]. IL-4, as an anti-inflammatory cytokine, showed no significant differences in any of the three groups. Levels of this cytokine were lower in patients with BD uveitis in comparison with the control group in the study of Nalbant et al. However, as mentioned already, only 40% of patients had active uveitis in our study, which could be considered as a confounding factor in the case of both studies comparison. The findings were different with respect to IL-4 in Sugiet et al.'s study and showed no significant differences in patients with BD uveitis in comparison with the control group, which shows data identical to our findings. Although it has been shown that the activation of BD is associated with IL-6 as a pre-inflammatory cytokine \[[@B14-jcm-06-00049],[@B16-jcm-06-00049]\], but its prominent role in involvement of central nervous system (CNS) due to cytokines elevated levels in cerebrospinal fluid of patients was proven in Wang et al.'s study \[[@B17-jcm-06-00049]\]. However, IL-6, in our study, was identical to that in Nalbant et al.'s survey, and there were no significant differences in IL-6 levels among the groups \[[@B14-jcm-06-00049]\]. Conversely, Bardak et al.'s study showed a disparity compared to Nalbant et al.'s and our studies. This means that IL-6 levels in BD uveitis in comparison with the control groups was reduced after treatments \[[@B18-jcm-06-00049]\]. Perhaps the reason for this difference originates from the small sample size of the study. Previous studies have shown that IL-8 as an essential cytokine in angiogenesis and chemotaxis of neutrophils rises in the active phase of the BD \[[@B16-jcm-06-00049]\]. There was no association between IL-8 and BD uveitis in our study, but such a relationship was shown in Durmazlar et al.'s study \[[@B19-jcm-06-00049]\]. IL-8 was reduced in patients with active BD uveitis in Nalbant et al.'s study, but there was an elevation in active BD uveitis, and it was reduced during therapies in Bardak et al.'s study \[[@B18-jcm-06-00049]\]. These findings are different from our results, which could be due to the small sample size. IL-10 levels as a Th~1~ cell inhibitor cytokine, showed no differences among the three groups in our study. However, an increase in IL-10 was only shown in aqueous humor in El-Asrar et al.'s study \[[@B20-jcm-06-00049]\]. This story was repeated in Ahn et al.'s study as well \[[@B4-jcm-06-00049]\]. Guenane et al.'s study showed the same results, but none of the samples of that study were directly obtained from the patient's serum (because of using sera and supernatants of peripheral blood mononuclear cells cultures), and cases without BD uveitis were not studied. Additionally, a comparison was performed only between controls and idiopathic uveitis. IL-12 plays an important role as a classical cytokine of Th1 cells in patients with visceral organs inflammation. In contrast, a role for this cytokine was not shown in BD uveitis based on our findings. As a non-specific cytokine, increasing in the level of IL-12 were demonstrated in idiopathic uveitis and BD uveitis in Guenane et al.'s study, which shows its role in uveitis regardless of the underlying disease. These findings contrast with those of Ahn et al.'s study \[[@B4-jcm-06-00049],[@B21-jcm-06-00049]\]. According to our findings, VEGF, TNFα, and IFNγ had no role in BD uveitis \[[@B4-jcm-06-00049],[@B14-jcm-06-00049],[@B21-jcm-06-00049]\]. Furthermore, IFNγ could be considered as a non-specific cytokine in uveitis according to findings described in \[[@B22-jcm-06-00049]\].

5. Conclusions and Suggestions {#sec5-jcm-06-00049}
==============================

The significant elevation of IL-2 in patients with uveitis indicates that it is likely the main role in the pathophysiology of BD uveitis and may be considered as a new target for refractory disease therapies. Studies with larger samples can help to obtain more accurate conclusions.
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jcm-06-00049-t001_Table 1

###### 

Demographic and clinical conditions of enrolled cases.

  ---------------------------------------------------------------------------------------------------------
  Demographic and Clinical Variables   BD with Uveitis\   Recovered Uveitis BD\   BD without Uveitis\   
                                       *n* = 26           *n* = 25                *n* = 24              
  ------------------------------------ ------------------ ----------------------- --------------------- ---
  Age                                  38.6 ± 3.1         40.1 ± 3.3              36.5 ± 3.2            

  Gender                               Female             5                       11                    6

  Male                                 21                 14                      18                    

  Ocular lesion                        26                 25                      \-\-\-\--             

  Aphthous stomatitis                  25                 24                      22                    

  Genital aphthosis                    13                 10                      21                    

  Skin lesion                          20                 18                      14                    

  CNS involvement                      \-\-\-\--          \-\-\-\--               \-\-\-\--             

  Vascular manifestation               3                  2                       7                     

  Arthritis                            4                  5                       10                    

  Pathergy test                        12                 12                      9                     
  ---------------------------------------------------------------------------------------------------------

jcm-06-00049-t002_Table 2

###### 

Levels of cytokines in venous blood samples of enrolled cases (μg/dL).

  Variable   Variable     BD without Uveitis   BD with Uveitis   \* *p*~vaule~                                    
  ---------- ------------ -------------------- ----------------- ----------------- ------------- ---------------- ------
  IL~2~      568 ± 537    351--470 (376)       506 ± 491         347--423 (365)    1658 ± 1184   451--672 (542)   0.02
  IL~4~      338 ± 262    152--223 (182)       296 ± 268         182--250 (200)    444 ± 363     181--266 (208)   0.12
  IL~6~      100 ± 66     62--124 (62)         88 ± 64           56--71 (63)       90 ± 73       57--76 (62)      0.23
  IL~8~      448 ± 334    150--338 (158)       435 ± 298         126--228 (164)    554 ± 394     117--200 (137)   0.14
  IL~10~     156 ± 106    105--154 (123)       145 ± 94          108--134 (115)    167 ± 148     106--138 (117)   0.59
  IL~12~     180 ± 161    95--190 (122)        182 ± 180         94--174 (114)     226 ± 217     95--214 (109)    0.89
  IL~15~     248 ± 203    139--204 (157)       245 ± 205         139--180 (160)    286 ± 225     160--182 (167)   0.25
  IL~17~     114 ± 101    56--102 (73)         100 ± 94          59--89 (67)       145 ± 108     59--79 (70)      0.97
  TNFα       165 ± 120    114--179 (123)       172 ± 109         113--200 (127)    166 ± 142     111--152 (124)   0.77
  VEGF       1156 ± 957   661--1396 (702)      1081 ± 920        622--1220 (696)   1028 ± 1024   592--890 (673)   0.51
  IFNγ       115 ± 68     78--143 (81)         109 ± 68          74--97 (79)       104 ± 73      73--93 (80)      0.41

***\**** *p*~value~ lower than 0.05 was considered statistically significant.
